30例局限期小细胞肺癌同步放化疗与序贯化放疗的疗效比较

摘要

Objective: To analyze the therapeutic effectiveness and toxicity of concurrent chemoradiotherapy and sequential chemoradiotherapy in SCLC patients. Method: Of 30 cases of limited - stage SCLC patient, 15 cases were treated with concurrent chemoradiotherapy( PTX+DDP+VP-16 ): the patients were treated with PPE chemotherapy in the first three cycles, and then the patients were treated with concurrent chemoradiotherapy in the fourth cycle. 2-4 cycles of consolidation chemotherapy were implemented when chemoradiotherapy was finished. Another 15 cases of patients were treated with sequential chemoradiotherapy : the radiotherapy was applied after three cycles of PPE chemotherapy were used, and 4 cycles of consolidation chemotherapy were implemented after radiotherapy was finished. Result: Compared with sequential chemoradiotherapy, the total effective rate of concurrent chemoradiotherapy was significantly enhanced ( 89. 4% vs. 76. 1% , P<0.05 ), but there was no significant difference in survival rate between concurrent chemoradiotherapy and sequential chemoradiotherapy ( P>0. 05 ). Conclusion: Compared with sequential chemoradiotherapy, concurrent chemoradiotherapy could increase the total effective rate of SCLC patients.%目的:比较分析小细胞肺癌同步放化疗与序贯放化疗的疗效及毒副反应.方法:30例局限期小细胞肺癌患者中的15例接受放疗同步联合化疗(PTX+DDP+VP-16)方案化疗:患者于前3个周期给予PPE方案化疗,从第4周期开始实施同步放化疗,放化疗结束后再巩固2-4个周期.另15例患者则接受放疗序贯化疗(序贯组):应用PPE方案化疗3个周期后进行放疗,放疗结束后再巩固化疗4个周期.结果:同步组和序贯组总有效率分别为89.4%和76.1%,同步组疗效优于序贯组(P＜0.05);而两组的生存率无显著差异(P＞0.05).结论:放疗同步化疗较序贯化放疗治疗小细胞肺癌能够提高治疗的有效率.